Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vifor Pharma Group

http://www.viforpharma.com/

Latest From Vifor Pharma Group

Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings

Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.

Europe Approvals

EU: Vifor Tries Again With Avacopan Using ‘More Powerful’ Data

Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.

Drug Review Europe

Vifor Builds Its Kidney Disease Focus With $80m Angion Deal

Deal helps Vifor pursue goal of becoming a leader in kidney disease therapies.

Companies Commercial

Vifor Confident About Prospects For Pruritus Dialysis Drug Korsuva

Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.

Deals Renal
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Vifor Pharma Management Ltd./ Subsidiaries: Aspreva Pharmaceuticals Corporation
    • Galenica Group
    • Relypsa, Inc.
    • Vifor Pharma
    • Vifor-Fresenius Medical Care Renal Pharma Ltd.
    • OM Pharma
UsernamePublicRestriction

Register